Published On: Mon, Sep 19th, 2016

Brokers Issue Forecasts for Biota Pharmaceuticals Inc.’s Q3 2017 Earnings (AVIR)

Biota Pharmaceuticals Inc. (NASDAQ:AVIR) – Investment analysts at Zacks Investment Research issued their Q3 2017 earnings per share estimates for shares of Biota Pharmaceuticals in a research report issued to clients and investors on Thursday. Zacks Investment Research analyst A. Dushyanth expects that the brokerage will post earnings of ($0.14) per share for the quarter.
Several other analysts have also commented on the stock. HC Wainwright assumed coverage on shares of Biota Pharmaceuticals in a research report on Wednesday, July 13th. They set a “buy” rating and a $5.00 price target for the company. FBR & Co reissued an “outperform” rating on shares of Biota Pharmaceuticals in a research report on Tuesday, May 31st.
Shares of Biota Pharmaceuticals (NASDAQ:AVIR) opened at 1.58 on Monday. The company’s 50-day moving average is $1.36 and its 200 day moving average is $1.47. The company’s market capitalization is $61.05 million. Biota Pharmaceuticals has a 12 month low of $1.23 and a 12 month high of $2.31.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/19/brokers-issue-forecasts-for-biota-pharmaceuticals-inc-s-q3-2017-earnings-avir.html

Biota Pharmaceuticals (NASDAQ:AVIR) last announced its earnings results on Wednesday, September 14th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.25 by $0.43. Biota Pharmaceuticals had a negative net margin of 272.04% and a negative return on equity of 46.02%.
Institutional investors have recently made changes to their positions in the stock. Gabelli Securities Inc. bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at approximately $314,000. BVF Inc. IL bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at approximately $292,000. California Public Employees Retirement System bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at approximately $139,000. Towerview LLC bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at approximately $224,000. Finally, Eagle Global Advisors LLC bought a new position in shares of Biota Pharmaceuticals during the second quarter valued at approximately $381,000. 34.53% of the stock is owned by hedge funds and other institutional investors.
About Biota Pharmaceuticals
Aviragen Therapeutics, Inc, formerly Biota Pharmaceuticals Inc, is a biopharmaceutical company. The Company is focused on the discovery and development of direct-acting antivirals to treat infections. It has approximately four product candidates in clinical development that address viral infections that have limited therapeutic options.

Receive News & Ratings for Biota Pharmaceuticals Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Biota Pharmaceuticals Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>